$332 Billion is the total value of Versant Venture Management, LLC's 7 reported holdings in Q4 2019. The portfolio turnover from Q3 2019 to Q4 2019 was 0.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| VCYT | Veracyte, Inc. | $33,654,963,000 | +16.3% | 1,205,407 | 0.0% | 10.14% | -9.4% | |
| GRTS | Gritstone Oncology, Inc. | $27,833,273,000 | +3.9% | 3,102,929 | 0.0% | 8.39% | -19.1% | |
| OCUL | Ocular Therapeutix, Inc. | $8,750,767,000 | +29.9% | 2,215,384 | 0.0% | 2.64% | +1.2% | |
| EYES | Second Sight Medical Products, Inc. | $3,336,034,000 | -10.0% | 4,492,975 | 0.0% | 1.00% | -29.9% | |
| CBAY | CymaBay Therapeutics, Inc. | $1,065,755,000 | -61.7% | 543,753 | 0.0% | 0.32% | -70.2% | |
| CLVS | Clovis Oncology, Inc. | $1,061,838,000 | +165.3% | 101,855 | 0.0% | 0.32% | +106.5% |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2020-01-21
Signatures
The EDGAR filing(s) were signed by:
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| CymaBay Therapeutics, Inc. | 35 | Q2 2023 | 10.2% |
| Clovis Oncology, Inc. | 32 | Q3 2022 | 53.2% |
| CRISPR Therapeutics AG | 23 | Q3 2023 | 77.2% |
| Ocular Therapeutix, Inc. | 22 | Q4 2020 | 18.0% |
| Gritstone Oncology, Inc. | 18 | Q3 2023 | 25.4% |
| Achaogen, Inc. | 18 | Q1 2019 | 23.5% |
| Adverum Biotechnologies, Inc. | 15 | Q3 2023 | 21.0% |
| Second Sight Medical Products, Inc. | 15 | Q3 2020 | 9.0% |
| Audentes Therapeutics, Inc. | 13 | Q3 2019 | 39.6% |
| Aligos Therapeutics, Inc. | 12 | Q3 2023 | 15.7% |
View Versant Venture Management, LLC's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-05-03 |
| 13F-HR | 2024-02-08 |
| 13F-HR | 2023-11-03 |
| 13F-HR | 2023-08-09 |
| 13F-HR | 2023-05-11 |
| 144 | 2023-04-20 |
| 13F-HR | 2023-02-09 |
| 13F-HR | 2022-11-10 |
| 13F-HR | 2022-08-11 |
| 13F-HR | 2022-05-10 |
View Versant Venture Management, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.